Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background: In most patients with atrial fibrillation (AF) and stroke, there is thrombotic
embolization from the left atrial appendage (LAA). Percutaneous closure of the LAA is a …

For the past 60 years, oral vitamin K antagonists (eg, warfarin, acenocoumarol,
phenprocoumon, fluindione) have been widely prescribed. 5 However, their impact in …

Aims In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be
weighed against the risk of bleeding. Time in therapeutic range (TTR) is an important tool to …

Importance Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non–
vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation …